Immunotherapy of infections caused by rare filamentous fungi

Clinical Microbiology and Infection

Volumn 18, Issue 2, 2012, Pages 134-139

  Katragkou, A ^a   Roilides, E ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Colony stimulating factors; Cytokine; Fungal infections; Fusariosis; Immunotherapy; Interleukin; Mucormycosis; Neutrophils; Scedosporiosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOSPORIN; DEFERASIROX; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRON CHELATING AGENT; ITRACONAZOLE; MEVINOLIN; POSACONAZOLE; RAPAMYCIN; RAVUCONAZOLE; TACROLIMUS; VORICONAZOLE;

ADJUVANT THERAPY; ANTIFUNGAL ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FUSARIOSIS; FUSARIUM MONILIFORME; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; GRANULOCYTE TRANSFUSION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; MORTALITY; MUCORMYCOSIS; NONHUMAN; PETRIELLIDIUM BOYDII; PHAGOCYTE; PRIORITY JOURNAL; PSEUDALLESCHERIASIS; REVIEW; SCEDOSPORIUM APIOSPERMUM; TREATMENT RESPONSE; ZYGOMYCETES;

FUNGI;

EID: 84856149943     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03689.x     Document Type: Review

References (74)

1. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10 (suppl 1): 48-66.
2. Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: analysis of 230 cases accrued by the Registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; doi: 10.1111/j.1469-0691.2010.03456.x. Jan 2 [Epub ahead of print].
3. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10 (suppl 1): 67-75.
4. Cortez KJ, Roilides E, Quiroz-Telles F et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21: 157-197.
5. Sun HY, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis 2011; 11: 301-311.
6. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301.
7. Hibbett DS, Binder M, Bischoff JF et al. A higher-level phylogenetic classification of the fungi. Mycol Res 2007; 111: 509-547.
8. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev 2011; 24: 411-445.
9. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
10. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556-569.
11. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743-1751.
12. Pagano L, Valentini CG, Fianchi L, Caira M. The role of neutrophils in the development and outcome of zygomycosis in haematological patients. Clin Microbiol Infect 2009; 15 (suppl 5): 33-36.
13. Kara IO, Tasova Y, Uguz A, Sahin B. Mucormycosis-associated fungal infections in patients with haematologic malignancies. Int J Clin Pract 2009; 63: 134-139.
14. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 207-214.
15. Pagano L, Ricci P, Tonso A et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. Gimema infection program (gruppo italiano malattie ematologiche maligne dell'adulto). Br J Haematol 1997; 99: 331-336.
16. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851-856.
17. Bethge WA, Schmalzing M, Stuhler G et al. Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. Haematologica 2005; 90 (suppl): ECR22: e62-e64.
18. Pappas PG. Immunotherapy for invasive fungal infections: from bench to bedside. Drug Resist Updat 2004; 7: 3-10.
19. Atallah E, Schiffer CA. Granulocyte transfusion. Curr Opin Hematol 2006; 13: 45-49.
20. Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant 2006; 38: 327-337.
21. Slavin MA, Kannan K, Buchanan MR, Sasadeusz J, Roberts AW. Successful allogeneic stem cell transplant after invasive pulmonary zygomycosis. Leuk Lymphoma 2002; 43: 437-439.
22. Mousset S, Hermann S, Klein SA et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005; 84: 734-741.
23. Grigull L, Beilken A, Schmid H et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer 2006; 14: 783-786.
24. Safdar A, Rodriguez GH, Lichtiger B et al. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006; 106: 2664-2671.
25. Safdar A. Antifungal immunity and adjuvant cytokine immune enhancement in cancer patients with invasive fungal infections. Clin Microbiol Infect 2007; 13: 1-4.
26. Simitsopoulou M, Roilides E, Maloukou A, Gil-Lamaignere C, Walsh TJ. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against zygomycetes. Mycoses 2008; 51: 147-154.
27. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005; 191: 1180-1187.
28. Rodriguez MM, Calvo E, Marine M, Pastor FJ, Fernandez-Ballart J, Guarro J. Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice. Antimicrob Agents Chemother 2009; 53: 3569-3571.
29. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 2004; 23: 769-773.
30. Garcia-Diaz JB, Palau L, Pankey GA. Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor. Clin Infect Dis 2001; 32: e145-e150.
31. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997; 24: 192-196.
32. Ma B, Seymour JF, Januszewicz H, Slavin MA. Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF. Leuk Lymphoma 2001; 42: 1393-1399.
33. Weng DE, Wilson WH, Little R, Walsh TJ. Successful medical management of isolated renal zygomycosis: case report and review. Clin Infect Dis 1998; 26: 601-605.
34. Zaoutis TE, Roilides E, Chiou CC et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007; 26: 723-727.
35. Roilides E, Zaoutis TE, Katragkou A, Benjamin DK Jr, Walsh TJ. Zygomycosis in neonates: an uncommon but life-threatening infection. Am J Perinatol 2009; 26: 565-573.
36. Roilides E, Zaoutis TE, Walsh TJ. Invasive zygomycosis in neonates and children. Clin Microbiol Infect 2009; 15 (suppl 5): 50-54.
37. Garcia-Covarrubias L, Barratt DM, Bartlett R, Van Meter K. Treatment of mucormycosis with adjunctive hyperbaric oxygen: five cases treated at the same institution and review of the literature. Rev Invest Clin 2004; 56: 51-55.
38. Ferguson BJ, Mitchell TG, Moon R, Camporesi EM, Farmer J. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 1988; 10: 551-559.
39. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005; 11: 515-517.
40. Tragiannidis A, Groll AH. Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis. Clin Microbiol Infect 2009; 15 (suppl 5): 82-86.
41. Segal E, Menhusen MJ, Shawn S. Hyperbaric oxygen in the treatment of invasive fungal infections: a single-center experience. Isr Med Assoc J 2007; 9: 355-357.
42. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008; 21: 620-625.
43. Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994; 45: 667-671.
44. Boelaert JR, De Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993; 91: 1979-1986.
45. Ibrahim AS, Gebermariam T, Fu Y et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117: 2649-2657.
46. Spellberg B, Andes D, Perez M et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009; 53: 3122-3125.
47. Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006; 50: 3968-3969.
48. Busca A, Marmont F, Locatelli F et al. Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy. Mycoses 2010; 53: 275-278.
49. Soummer A, Mathonnet A, Scatton O et al. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob Agents Chemother 2008; 52: 1585-1586.
50. Dannaoui E, Schwarz P, Lortholary O. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother 2009; 53: 3549-3551.
51. Narreddy S, Manavathu E, Chandrasekar PH, Alangaden GJ, Revankar SG. In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes. J Antimicrob Chemother 2010; 65: 701-703.
52. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007; 7: 358-368.
53. Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 2007; 44: 1089-1090.
54. Roze LV, Linz JE. Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus. Fungal Genet Biol 1998; 25: 119-133.
55. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006; 50: 96-103.
56. Galgoczy L, Papp T, Lukacs G, Leiter E, Pocsi I, Vagvolgyi C. Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive zygomycetes. FEMS Microbiol Lett 2007; 270: 109-115.
57. Lukacs G, Papp T, Nyilasi I, Nagy E, Vagvolgyi C. Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol 2004; 42: 5400-5402.
58. Sun HY, Singh N. Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis 2009; 48: 745-755.
59. Tadros TS, Workowski KA, Siegel RJ, Hunter S, Schwartz DA. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis. Hum Pathol 1998; 29: 1266-1272.
60. Gil-Lamaignere C, Roilides E, Maloukou A, Georgopoulou I, Petrikkos G, Walsh TJ. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 2002; 50: 1027-1030.
61. Gil-Lamaignere C, Roilides E, Mosquera J, Maloukou A, Walsh TJ. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002; 46: 2234-2237.
62. Gil-Lamaignere C, Winn RM, Simitsopoulou M, Maloukou A, Walsh TJ, Roilides E. Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. Med Mycol 2005; 43: 253-260.
63. Ortoneda M, Capilla J, Pujol I et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother 2002; 49: 525-529.
64. Ortoneda M, Capilla J, Pastor FJ, Serena C, Guarro J. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn Microbiol Infect Dis 2004; 50: 247-251.
65. Simitsopoulou M, Gil-Lamaignere C, Avramidis N et al. Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob Agents Chemother 2004; 48: 3801-3805.
66. Bouza E, Munoz P, Vega L, Rodriguez-Creixems M, Berenguer J, Escudero A. Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor. Clin Infect Dis 1996; 23: 192-193.
67. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695-704.
68. Dotis J, Simitsopoulou M, Dalakiouridou M et al. Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: comparison with Aspergillus fumigatus. J Antimicrob Chemother 2008; 61: 810-817.
69. Roilides E, Lyman CA, Armstrong D, Stergiopoulou T, Petraitiene R, Walsh TJ. Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani. Mycoses 2006; 49: 109-113.
70. Winn RM, Gil-Lamaignere C, Roilides E et al. Effects of interleukin-15 on antifungal responses of human polymorphonuclear leukocytes against Fusarium spp. and Scedosporium spp. Cytokine 2005; 31: 1-8.
71. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90: 999-1008.
72. Dignani MC, Anaissie EJ, Hester JP et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997; 11: 1621-1630.
73. Spielberger RT, Falleroni MJ, Coene AJ, Larson RA. Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient. Clin Infect Dis 1994; 18: 490-491.
74. Rodriguez CA, Lujan-Zilbermann J, Woodard P, Andreansky M, Adderson EE. Successful treatment of disseminated fusariosis. Bone Marrow Transplant 2003; 31: 411-412.